Rad51-BRCA2 interaction inhibitors (Taivex Therapeutics)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameRad51-BRCA2 interaction inhibitors (Taivex Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBreast cancer type 1 susceptibility protein inhibitorsDNA repair protein RAD51 homolog 1 inhibitors
TargetsDNA repair protein RAD51 homolog 1Breast cancer type 1 susceptibility protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTaivex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaivex Therapeutics
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A